Jessica Atkins
Advanced Heart Failure and Transplant Cardiology · Charleston, SCNPI 1285000349
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,396 of the $1,908 with a category attached, or 73.2%. 5 manufacturers reported payments, led by Edwards Lifesciences at 44.7% of the total. Reporting peaked in 2022 at $795 and has fallen 53.4% since, to $371 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in SC, where the typical reported total is $13,902.
Across 11 payments — averaging $173.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$852
- Boston Scientific$426
- Ancora Heart, Inc.$371
- Abbott$174
- Cvrx, Inc.$86
Across 2 payments — averaging $2668.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$5K
What the payments were for
- Travel & lodging$51227%
- Food & beverage$1,39673%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 3 | $852 |
| Boston Scientific | 4 | $426 |
| Ancora Heart, Inc. | 1 | $371 |
| Abbott | 2 | $174 |
| Cvrx, Inc. | 1 | $86 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,908 in reported general payments places this provider in the 5th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.
See all advanced heart failure and transplant cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 99 | $111,898 |
| JardianceEmpagliflozin | 52 | $54,619 |
| FarxigaDapagliflozin Propanediol | 48 | $44,143 |
| EliquisApixaban | 34 | $38,000 |
| Metoprolol Succinate | 77 | $1,060 |
| Spironolactone | 74 | $848 |
| Bumetanide | 20 | $654 |
| Atorvastatin Calcium | 45 | $461 |
| Carvedilol | 51 | $403 |
| Rosuvastatin Calcium | 25 | $303 |
| Losartan Potassium | 26 | $233 |
| Furosemide | 32 | $163 |
| Amlodipine Besylate | 18 | $76 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $32 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Charleston
- Ryan TedfordCharleston$528K
- Michael ZileCharleston$358K
- Daniel JudgeCharleston$116K
- Ramsey WehbeCharleston$108K
- Sheldon LitwinCharleston$86K
- Brian HoustonCharleston$43K
- Jan GriffinCharleston$23K
- Adrian VanbakelCharleston$21K
- Daniel SilvermanCharleston$11K
- Vishal RaoCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.